Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma
Sarcopenia, which represents the degenerative and systemic loss of skeletal muscle mass, is a multifactorial syndrome caused by various clinical conditions. Sarcopenia reflects not only frailty and poor general health status, but also the possible presence of advanced or progressive cancer or cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/20/3/760 |
| _version_ | 1811325640473837568 |
|---|---|
| author | Hiroshi Fukushima Yasuhisa Fujii Fumitaka Koga |
| author_facet | Hiroshi Fukushima Yasuhisa Fujii Fumitaka Koga |
| author_sort | Hiroshi Fukushima |
| collection | DOAJ |
| description | Sarcopenia, which represents the degenerative and systemic loss of skeletal muscle mass, is a multifactorial syndrome caused by various clinical conditions. Sarcopenia reflects not only frailty and poor general health status, but also the possible presence of advanced or progressive cancer or cancer cachexia. Therefore, sarcopenia affects the management of cancer-bearing patients, including those with urothelial carcinoma. Recently, growing evidence has shown that sarcopenia is significantly associated with higher rates of treatment-related complications and worse prognosis in patients with urothelial carcinoma, including muscle-invasive bladder cancer, upper tract urothelial carcinoma, and advanced urothelial carcinoma. Moreover, several studies reported that a post-therapeutic increase in skeletal muscle mass predicts favorable prognosis in urothelial carcinoma patients. To further explore the role of sarcopenia in the management of urothelial carcinoma patients, comprehensive understanding of its pathophysiology is vital. In this article, we reviewed the metabolic and molecular basis of cancer cachexia and sarcopenia. From this viewpoint, we discussed the possible mechanism of changes in skeletal muscle mass during the course of treatment. |
| first_indexed | 2024-04-13T14:36:41Z |
| format | Article |
| id | doaj.art-2669f37c1b96438ab1bbee86aa090322 |
| institution | Directory Open Access Journal |
| issn | 1422-0067 |
| language | English |
| last_indexed | 2024-04-13T14:36:41Z |
| publishDate | 2019-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-2669f37c1b96438ab1bbee86aa0903222022-12-22T02:43:01ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-02-0120376010.3390/ijms20030760ijms20030760Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial CarcinomaHiroshi Fukushima0Yasuhisa Fujii1Fumitaka Koga2Department of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanDepartment of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanDepartment of Urology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, JapanSarcopenia, which represents the degenerative and systemic loss of skeletal muscle mass, is a multifactorial syndrome caused by various clinical conditions. Sarcopenia reflects not only frailty and poor general health status, but also the possible presence of advanced or progressive cancer or cancer cachexia. Therefore, sarcopenia affects the management of cancer-bearing patients, including those with urothelial carcinoma. Recently, growing evidence has shown that sarcopenia is significantly associated with higher rates of treatment-related complications and worse prognosis in patients with urothelial carcinoma, including muscle-invasive bladder cancer, upper tract urothelial carcinoma, and advanced urothelial carcinoma. Moreover, several studies reported that a post-therapeutic increase in skeletal muscle mass predicts favorable prognosis in urothelial carcinoma patients. To further explore the role of sarcopenia in the management of urothelial carcinoma patients, comprehensive understanding of its pathophysiology is vital. In this article, we reviewed the metabolic and molecular basis of cancer cachexia and sarcopenia. From this viewpoint, we discussed the possible mechanism of changes in skeletal muscle mass during the course of treatment.https://www.mdpi.com/1422-0067/20/3/760sarcopeniabiomarkerurothelial carcinoma |
| spellingShingle | Hiroshi Fukushima Yasuhisa Fujii Fumitaka Koga Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma International Journal of Molecular Sciences sarcopenia biomarker urothelial carcinoma |
| title | Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma |
| title_full | Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma |
| title_fullStr | Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma |
| title_full_unstemmed | Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma |
| title_short | Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma |
| title_sort | metabolic and molecular basis of sarcopenia implications in the management of urothelial carcinoma |
| topic | sarcopenia biomarker urothelial carcinoma |
| url | https://www.mdpi.com/1422-0067/20/3/760 |
| work_keys_str_mv | AT hiroshifukushima metabolicandmolecularbasisofsarcopeniaimplicationsinthemanagementofurothelialcarcinoma AT yasuhisafujii metabolicandmolecularbasisofsarcopeniaimplicationsinthemanagementofurothelialcarcinoma AT fumitakakoga metabolicandmolecularbasisofsarcopeniaimplicationsinthemanagementofurothelialcarcinoma |